P.S.K Biosciences, founded in 2021, is a Nanjing, China-based company under Simcere Pharmaceutical Group, focused on pioneering exosome-based drug development. we have established two complementary, proprietary technology platforms: an engineered exosome delivery system for nucleic acid drugs and a natural exosome subpopulation platform for first-in-class biologic therapeutics.

Engineered Exosome Platform: We specialize in tissue-tropic drug delivery using engineered exosomes, with a core focus on blood-brain barrier (BBB) penetration. Our platform employs advanced genome editing technologies to achieve breakthroughs in loading siRNA and mRNA therapeutics into exosomes. Furthermore, we have overcome the critical industry bottleneck of large-scale manufacturing for exosome-shRNA/mRNA complexes.

Natural Exosome Platform: We are the first to isolate functionally distinct exosome subpopulations with demonstrated superior and differentiated efficacy. Our platform is the only one with completed IIT clinical studies showing compelling human data.